Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other financing activities: 2009-2024

Historic Other financing activities for Ironwood Pharmaceuticals (IRWD) over the last 11 years, with Dec 2024 value amounting to $11.0 million.

  • Ironwood Pharmaceuticals' Other financing activities rose 100.01% to $1,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $9.0 million, marking a year-over-year increase of 131.56%. This contributed to the annual value of $11.0 million for FY2024, which is 174.98% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Other financing activities stood at $11.0 million for FY2024, which was up 174.98% from $4.0 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Other financing activities ranged from a high of $19.7 million in FY2021 and a low of $4.0 million during FY2023.
  • Moreover, its 3-year median value for Other financing activities was $11.0 million (2024), whereas its average is $8.9 million.
  • Its Other financing activities has fluctuated over the past 5 years, first plummeted by 66.03% in 2023, then soared by 174.98% in 2024.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Other financing activities stood at $18.5 million in 2020, then climbed by 6.15% to $19.7 million in 2021, then slumped by 40.09% to $11.8 million in 2022, then tumbled by 66.03% to $4.0 million in 2023, then spiked by 174.98% to $11.0 million in 2024.